Polish Biotech Science4Beauty Raises EUR 1.6M to Scale Innovative Conotoxin Platform for the Beauty Industry
WARSAW, 31 August – Polish deep-tech biotech Science4Beauty, which develops next-generation advanced skincare products based on its proprietary, patented recombinant protein production technology, has closed a EUR 1.6 million investment round. The raised capital will allow the company to scale sales, accelerate R&D on additional bioactive molecules for dermatology and aesthetic medicine, and drive international expansion. The funding round was led by 4growth VC, with participation from Hard2beat and business angels.
Science4Beauty is a biotechnology platform that designs, produces, and purifies recombinant proteins and bioactive peptides in its own genetic engineering laboratory. The company specializes in developing innovative active ingredients for advanced skincare and dermatology. The startup’s flagship solution is the Miorelaxant Magic™ product line, powered by proprietary conotoxin – a bioactive molecule mimicking the mechanism of sea snail venom that relaxes facial muscles and smooths wrinkles, delivering a needle-free “botox in a cream” effect.
The efficacy of this solution has been clinically proven, demonstrating up to a 48% reduction in wrinkle depth. Furthermore, clinical trials confirmed a key value proposition for aesthetic medicine clinics: regular application extends the results of botulinum toxin treatments by approximately 60 days.
– Science4Beauty is not just a line of finished skincare products, but above all a complete and highly scalable biotechnology platform. Today, we are commercializing the Miorelaxant Magic™ line, which has gained strong recognition among patients and aesthetic medicine practitioners, but our research pipeline extends much further. We are working on new applications for our technology, including treatments for hyperhidrosis and dermatological conditions such as rosacea, as well as innovative delivery systems like microneedle patches. The raised capital will allow us to scale production and efficiently launch distribution channels in key international markets. We are thrilled that VC funds have recognized the uniqueness of our technology and the maturity of our business model – says Magdalena Janczewska, CEO of Science4Beauty.
Market Potential and Business Model
This investment arrives at a pivotal moment for the global anti-aging market, which is projected to grow from $56 billion in 2025 to $108 billion by 2033. The fastest-growing market segment comprises innovative, science-backed clean biotech products that offer an effective, non-invasive alternative to traditional aesthetic procedures.
The business model focuses on commercialization across two main pillars: B2B sales directly to aesthetic medicine clinics, and direct-to-consumer (DTC) e-commerce via science4beauty.net. To date, the company has brought 5 products to market and generated over PLN 500,000 (~€115,000) in revenue in 2025 without marketing spend.
– At 4growth VC, we look for deep-tech companies – particularly in health and life sciences – that seamlessly combine breakthrough science with effective commercial execution. Science4Beauty meets these criteria entirely. The company’s core competitive advantages include its in-house laboratory, intellectual property protected across 10 jurisdictions, and clinical trial-backed product efficacy. Previous grant funding of over PLN 10 million (~€2.3M) from the National Centre for Research and Development (NCBR) significantly de-risked the technology. We see immense potential in the innovative dermatology market and believe Science4Beauty has all the assets required to become a global player in the smart luxury segment – highlights Tomasz Pasiewicz, Managing Partner at 4growth VC.
– At Hard2beat, we move away from the traditional paradigm where biotech is associated strictly with classic drug discovery, burdened by multi-year development cycles and high regulatory risks. Science4Beauty is a prime example of leveraging synthetic biology and protein engineering for rapid commercialization. Applying advanced recombinant peptide expression – such as the conotoxin-based molecule in the Miorelaxant Magic™ line – delivers targeted, clinically validated products to the market in a fraction of the time typically required by biotech startups. What attracted us is the platform potential of this technology and its entry into the medical-grade skincare market, combining the attractive margin profile of the beauty industry with the high entry barriers of the pharma sector – says Konrad Trzyna, Managing Partner at Hard2beat.
About Science4Beauty
Science4Beauty is a Polish deep-tech biotech startup founded in 2020 by an experienced team of female scientists and life-science executives: Magdalena Janczewska, Anna Mazurkiewicz-Pisarek, PhD, Alina Mazurkiewicz, and Agata Stefanek, alongside Prof. Tomasz Ciach as scientific advisor. Science4Beauty designs, produces, and purifies recombinant proteins and bioactive peptides for advanced skincare, dermatology, and medicine. The company’s breakthrough achievement is the bioproduction of recombinant conotoxin – the active ingredient behind the Miorelaxant Magic™ product line, acting as a non-invasive alternative and complementary booster for aesthetic treatments. Science4Beauty operates an in-house certified Category I GMM genetic engineering laboratory and holds patent filings across 10 jurisdictions. Earlier R&D was funded by grants from the National Centre for Research and Development (NCBR).
